Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2020-10-05 Regulatory Filings
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia’s partner Elevar Therapeutics signs agreement with Taiba Middle East FZ LLC for commercialization of Apealea® in the Middle East and North Africa Region
Regulatory Filings Classification · 95% confidence The document is a press release dated October 05, 2020, announcing a commercialization agreement between Oasmia's partner (Elevar Therapeutics) and a regional distributor (Taiba Middle East FZ LLC) for the drug Apealea® in the MENA region. It details the terms, background on the drug, and quotes from CEOs. This type of announcement, which is a material event but not a formal regulatory filing like a 10-K, ER, or IR, typically falls under general regulatory announcements or press releases. Since it is not a specific financial report (10-K, IR, ER), a management change (MANG), or a director trade (DIRS), the most appropriate general category for a significant corporate event announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements. The document length (4932 chars) is substantial enough that it is the announcement itself, not just a notice of publication (RPA).
2020-10-05 English
Oasmias partner Elevar Therapeutics ingår avtal med Taiba Middle East FZ LLC för kommersialisering av Apealea® i Mellanöstern och Nordafrika
Regulatory Filings Classification · 95% confidence The document is a press release dated October 5, 2020, announcing a commercialization and distribution agreement between Oasmia's partner (Elevar Therapeutics) and a third party (Taiba Middle East FZ LLC) for the drug Apealea® in the MENA region. It details the terms of the agreement, the drug's status, and includes quotes from management. The text explicitly states it is a 'Pressmeddelande' (Press Release) and contains language typical of corporate news announcements regarding business development and partnerships. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report, fits best under the general category for regulatory announcements or news releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement of this nature, as it is a public disclosure required by market rules (implied by the MAR reference at the end), but it is not a specific financial report or management disclosure form listed.
2020-10-05 Swedish
Oasmia väcker talan mot bolagets tidigare styrelse
Legal Proceedings Report Classification · 98% confidence The document is a press release dated September 25, 2020, announcing that Oasmia Pharmaceutical AB is filing a lawsuit against its former board members for mismanagement, including issues related to a previous ownership dispute, prohibited loans, tax audits, and group litigation costs. The text details the basis for the claim (approx. 30 MSEK) and references prior internal reviews (Deloitte audit, shareholder meeting decisions). This type of announcement regarding significant legal action and potential liability falls under the category of reporting on significant legal matters involving the company. This aligns best with the Legal Proceedings Report (LTR) definition, which covers 'Updates on significant lawsuits, regulatory actions, or legal matters involving the company.' It is not an earnings release (ER), a full annual report (10-K), or a management discussion (MDA), but a specific legal update.
2020-09-25 Swedish
Oasmia Brings an Action against the Former Board of Directors
Legal Proceedings Report Classification · 95% confidence The document text announces that Oasmia is bringing an action (lawsuit) against its former Board of Directors regarding past management issues, referencing findings from the 2019 AGM and an audit review. This is a specific announcement regarding legal action and accountability of management/directors concerning past decisions. While it relates to the board (MANG) and legal matters (LTR), the core subject is the initiation of a lawsuit based on findings from a prior meeting and audit. Since the document is a press release announcing a legal proceeding against former directors, it most closely aligns with 'Legal Proceedings Report' (LTR). It is not a formal regulatory filing like a 10-K or IR, nor is it a general regulatory announcement (RNS) as it concerns a specific, material legal event.
2020-09-25 English
Stämmokommuniké från årsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is titled "Stämmokommuniké från årsstämma i Oasmia Pharmaceutical AB" (Minutes/Communication from the Annual General Meeting in Oasmia Pharmaceutical AB). It details the resolutions passed at the AGM held on September 9, 2020, covering financial statements approval, dividend decisions, board elections, auditor re-election, changes to the articles of association, and authorization for future share issues. This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). Although it summarizes decisions, it is the official communication of those decisions, not just a proxy solicitation (PSI) or a general regulatory filing (RNS).
2020-09-09 Swedish
Report from Annual General Meeting of Oasmia Pharmaceutical AB
AGM Information Classification · 100% confidence The document is explicitly titled 'Report from Annual General Meeting of Oasmia Pharmaceutical AB' and details the resolutions adopted at this meeting, including the adoption of financial statements, board elections, fee structures, auditor re-election, and authorization for future share issues. This content directly corresponds to the definition of AGM Information.
2020-09-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.